Updated
Liver
Cordyceps, shiitake, antrodia and four others have been tried in people for this. The register's own words for this are hepatitis, liver, non-alcoholic fatty liver.
Eleven registered trials have looked at this, and not one of them has reported a result.
Species by species
| Species | How far it has got | Trials | With a result | Randomised | Commonly taken for it |
|---|---|---|---|---|---|
| Cordyceps Cordyceps militaris | A first trial | 2 | 0 | 1 | — |
| Shiitake Lentinula edodes | A first trial | 2 | 0 | 1 | — |
| Antrodia Taiwanofungus camphoratus | A first trial | 1 | 0 | 1 | yes |
| Zhu ling Polyporus umbellatus | A first trial | 1 | 0 | 1 | — |
| Turkey tail Trametes versicolor | A first trial | 0 | 0 | 1 | — |
| Poria Wolfiporia extensa | Being tested now | 2 | 0 | 0 | — |
| Reishi Ganoderma lucidum | Being tested now | 2 | 0 | 0 | yes |
| Royal sun agaric Agaricus subrufescens | Being tested now | 1 | 0 | 0 | yes |
| Mesima Phellinus linteus | Laboratory work | 0 | 0 | 0 | yes |
Commonly taken for liver, with the work still in the laboratory rather than in people: Mesima.
The trials themselves
Every registered study that names one of these species and a condition the register files under this heading.
| Register | Study | Condition | People | Status | Result posted | Dose in the protocol |
|---|---|---|---|---|---|---|
| NCT04846010 | Recovering Damaged Cells for Sequelae Caused by COVID-19, SARS-CoV-2 | Sequelae of; Infection, Post Infection Glomerulonephritis | 2000 | Unknown | — | — |
| NCT04846010 | Recovering Damaged Cells for Sequelae Caused by COVID-19, SARS-CoV-2 | Sequelae of; Infection, Post Infection Glomerulonephritis | 2000 | Unknown | — | — |
| NCT07017426 | Fuzheng Huayu Tablets Reduce the Occurrence of Re-Decompensation Events in Patients With First Decompensation | Decompensated Hepatitis B Cirrhosis | 432 | Not yet recruiting | — | — |
| NCT07534241 | Hepatoprotective Effects of Reishi Mushroom- (Ganoderma Lucidum) Among Metabolic Dysfunction-associated Fatty | Lipid Profile, Liver Biomarkers | 102 | Recruiting | — | 250 mg |
| NCT07118735 | AHCC® as Immune Modulator in Cancer Patients Treated With Immunotherapy | Liver Cancer, Hepatocellular Carcinoma | 94 | Not yet recruiting | — | 3 g |
| NCT03625102 | A Randomized, Double-Blind Trial of Antroquinonol in Patients With Chronic Hepatitis B | HBV | 60 | Completed | — | 50 mg |
| NCT06266559 | Efficacy Evaluation of Chang Geng Healthy Drink on Patients With Non-alcoholic Fatty Liver Disease | Non-Alcoholic Fatty Liver Disease | 60 | Unknown | — | — |
| NCT06138444 | Effect of Cordyceps Militaris Beverage on the Immune Response | Healthy | 40 | Completed | — | — |
| NCT07564947 | Impact of Ganoderma Lucidum on NRF2 Levels and Antioxidant Status in Metabolic Asscociated Fatty Liver Disease | MAFLD, Fatty Liver | 40 | Enrolling by invitation | — | — |
| NCT02690103 | Response Modifier (Arabinoxylan Rice Bran/MGN-3/Biobran) With Interferon-Alpha for HCV | Hepatitis C, Chronic | 37 | Completed | — | 180µg, 1g per day |
| NCT00564811 | Effect of Agaricus Blazei (Murrill) ss. Heinemann (Sun Mushroom) | Hepatitis C, Nutritional Status | 10 | Completed | — | 10 g |
Memory and focusMood and anxietySleepFatigue and energyImmune functionCancer, supportive and adjuvantBlood sugarCholesterol and lipidsGut and microbiomeExercise performanceInflammationSkinLungs and breathingKidneyNerve repairAllergyMouth and gumsLibido and fertilityBlood and clottingViral infectionBacterial infectionWound healingFluid retentionNutrition